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Blood oxygen level dependent (BOLD) imaging in awake mice was used to identify dif-
ferences in brain activity between wild-type, HETzQ175, and HOMzQ175 genotypes in
response to the odor of almond. The study was designed to see how alterations in the
huntingtin gene in a mouse model of Huntington’s disease would affect the perception
and processing of almond odor, an evolutionarily conserved stimulus with high emotional
and motivational valence. Moreover, the mice in this study were “odor naïve,” i.e., never
having smelled almond or any nuts. Using a segmented, annotated MRI atlas of the mouse
and computational analysis, 17 out of 116 brain regions were identified as responding dif-
ferently to almond odor across genotypes. These regions included the glomerulus of the
olfactory bulb, forebrain cortex, anterior cingulate, subiculum, and dentate gyrus of the hip-
pocampus, and several areas of the hypothalamus. In many cases, these regions showed a
gene-dose effect with HETzQ175 mice showing a reduction in brain activity from wild-type
that is further reduced in HOMzQ175 mice. Conspicuously absent were any differences in
brain activity in the caudate/putamen, thalamus, CA3, and CA1 of the hippocampus and
much of the cortex. The glomerulus of the olfactory bulb in HOMzQ175 mice showed a
reduced change in BOLD signal intensity in response to almond odor as compared to the
other phenotypes suggesting a deficit in olfactory sensitivity.
Keywords: BOLD fMRI, neural pathways, reward processing, awake animal imaging, mouse model of Huntington’s
disease, huntingtin-associated protein 1, feeding behavior
INTRODUCTION
Huntington’s disease (HD) is characterized by motor dysfunction
and cognitive decline, and is caused by an autosomal dominant
expansion of CAG repeats in the huntingtin (HTT ) gene. HD
patients often present with non-motor symptoms that include
cognitive dysfunction (1, 2), affective disorders (3), and sleep and
circadian rhythm disruptions, which can all precede the onset of
motor dysfunction. In a recent imaging study, Enzi and cowork-
ers reported deficits in reward processing in pre-manifest (near
but not symptomatic) HD patients (4). Here, we use awake ani-
mal imaging to study the emotional and cognitive neural circuits
involved in reward processing in a pre-symptomatic transgenic
mouse model of HD. Indeed, with non-invasive ultra-high field,
functional magnetic resonance imaging (fMRI) in awake animals,
it is possible to image changes in brain activity across distrib-
uted, integrated neural circuits with high temporal and spatial
resolution (5). When combined with the use of 3D segmented,
annotated, brain atlases, and computational analysis it is possi-
ble to reconstruct the neural circuits involved in emotional and
cognitive processes.
To this end, we report here, for the first time, the develop-
ment and application of tools for blood oxygen level dependent
(BOLD) imaging in awake mice without any invasive surgical
preparation. This new technology was applied to the study of the
zQ175 knock-in mice containing a human mutant (mHtt) allele
with the expanded CAG repeat (~179 repeats) within the native
mouse huntingtin gene (6). This animal model is representative
of HD in humans from genetic, neural, and behavioral aspects.
Both homozygous (HOM) and heterozygous (HET)zQ175 mice
exhibit first signs of motor symptoms from 3 to 4 months of age
and behavioral deficits accompanied by marked brain atrophy and
brain metabolite changes by 8 months (6, 7). Indeed, the knock-in
mouse models of HD show disease progression in the HET geno-
type as protracted and more subtle than HOM providing a better
opportunity to identify biomarkers of early neuropathology prior
to the onset of motor dysfunction (6–9).
The present studies were conducted on year old wild-type, HET
zQ175, and HOM zQ175 mice. We show here that there are sig-
nificant differences in brain activity in response to the smell of
a highly desirable food – almond. In this study, all animals were
“odor naïve” to this evolutionarily conserved stimulus (10) rais-
ing the following question. How has this single gene mutation
altered the perception of this highly important odorant signal?
The technology and approach used in this study addresses this
question by showing that imaging awake mice is technically fea-
sible and that the BOLD signal changes are robust and provide
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the means of differentiating brain activity between genotypes to
an olfactory stimulus that carries high emotional and motivation
valence. When these BOLD signal changes are registered to an MRI
based, 3D segmented annotated mouse brain atlas, it is possible to
identify the integrated neural circuits affected by this single gene
mutation.
MATERIALS AND METHODS
ANIMAL CARE
Wild-type mice (C57B/L6J) (n= 5 male, 6 female) and knock-
in zQ175 HET (n= 4 male, 6 female) and HOM (n= 5 male, 5
female) mice (courtesy of Psychogenics Inc., Tarrytown, NY, USA)
were maintained on a 12:12 h light:dark cycle with a lights on at
07:00 hours. All mice from each phenotype were born between
16 and 18 August 2011 and scanned ~1 year later. Animals were
allowed access to food and water ad libitum. All the mice were
housed in groups of up to four per cage with mice of the same
genotype and gender. Mice were cared for in accordance with
the guidelines published in the Guide for the Care and Use of
Laboratory Animals (National Institutes of Health Publications
No. 85–23, Revised 1985) and adhered to the National Institutes
of Health and the American Association for Laboratory Animal
Science guidelines. The protocols used in this study were in com-
pliance with the regulations of the Institutional Animal Care and
Use Committee at Northeastern University.
AWAKE MOUSE IMAGING SYSTEM
Presented in Figure 1 are the different components of the mouse
imaging system showing a radiofrequency coil and MR compatible
restraining system for imaging awake or anesthetized mice ranging
in the size from 10 to 50 g (Animal Imaging Research, Holden, MA,
USA). The quadrature transmit/receive volume coil (ID 38 mm)
provides excellent anatomical resolution and signal–noise-ratio
for voxel-based fMRI. The unique design of the holder essentially
stabilizes the head in a cushion, minimizing any discomfort nor-
mally caused by ear bars and pressure points used to immobilize
the head for awake animal imaging. The mouse holder can be
inserted and withdrawn while the volume coil is positioned in the
magnet greatly reducing the set-up time between studies. A movie
showing the set-up of a mouse for awake imaging is available at
http://www.youtube.com/watch?v=W5Jup13isqw.
It should be noted, Desai and colleagues used BOLD imag-
ing and optogenetics to study integrated neural circuits in awake
mice (11). Their experimental design required that each animal be
implanted with a head post. In our system, this is not necessary,
eliminating the confound of surgery. Moreover, following accli-
mation it is possible to image multiple animals during an imaging
session. The data presented on motion detection in Figure 2 were
gathered from 29 mice imaged over a 8 h period. This was possible
because the total scan time (tripilot, anatomy, and functional) was
<15 min each. In addition, once the quadrature transmit/receive
volume coil was position in the magnet, tuned, and matched, it
was never moved or adjusted. One mouse holder (see Figure 1)
was simply replaced with a second as noted above.
One limitation in the mouse imaging system is the presentation
of visual and auditory stimuli. While it is possible to inject drugs
(IP, SC, and IV), electrically stimulate fore and hind paws, and run
flexible fiber optics to the head through portals in the body tube,
the eyes are not easily accessible to visual stimuli. The auditory
canal of the ears is blocked by the cushioned head pad, dampen-
ing, if not eliminating, auditory stimuli. However, the presentation
of odors is actually facilitated by the design of the head holder. The
front incisors of the mouse are locked onto a bite bar by pulling
the snout into a beveled nose cone. The cone is perforated so as
not to restrict the flow of air from the nostrils or mouth. A hollow
tube extends from the tip of the nose cone providing a route for
administering volatile anesthetics, e.g., isoflurane, carbon dioxide
gas as shown in Figure 3 or odors that carry emotional and/or cog-
nitive messages. Furthermore, olfaction is an especially important
sensory modality in rodents.
ACCLIMATION AND MOTION DETECTION
A week prior to the first imaging session, all animals were accli-
mated to the imaging system before scanning. Animals were
secured into their holding system while anesthetized with 2–3%
isoflurane. Following cessation of isoflurane, fully conscious mice
were put into a “mock scanner” (a black box with a tape recording
of MRI pulses) for 30 min for four consecutive days. Acclima-
tion in awake animal imaging significantly reduces physiological
effects of the autonomic nervous system including heart rate, res-
piration, corticosteroid levels, and motor movements (12) helping
to improve contrast-to-noise and image quality. In these studies,
motion artifact was greatly reduced as shown in the time-course
data in Figure 2 as estimated by a 3D rigid body model with 6
degrees of freedom for translational and rotational movement.
Data were collected from 29 awake mice imaged for 5 min. The
average motion is<20µ.
IMAGING ACQUISITION AND PULSE SEQUENCE
Experiments were conducted using a Bruker Biospec 7.0 T/20-cm
USR horizontal magnet (Bruker, Billerica, MA, USA) and a 20-
G/cm magnetic field gradient insert (ID= 12 cm) capable of a
120-µs rise time (Bruker). At the beginning of each imaging ses-
sion, a high-resolution anatomical data set was collected using the
RARE pulse sequence (20 slice; 0.75 mm; FOV 2.5 cm; data matrix
256× 256; TR 2.1 s; TE 12.4 ms; Effect TE 48 ms, NEX 6; 6.5 min
acquisition time). Functional images were acquired using a multi-
slice half Fourier acquisition single shot turbo spin echo (HASTE)
pulse sequence. With this sequence it is possible to collect 20,
0.75 mm thick, axial slices in <6 s. With a FOV of 2.5 cm and a
data matrix of 96× 96, the in-plane pixel functional resolution
for these studies was 260µm2.
The major advantage to a spin echo pulse sequence is its tol-
erance to magnetic susceptibility and motion artifact. The 180°
RF refocusing pulse corrects for the lack of field homogeneity,
chemical shift, tissue artifacts, and magnetic susceptibility from
static dephasing in BOLD imaging. The disadvantage is loss of
signal contrast. The problem of sensitivity can be addressed with
higher field strengths where the BOLD signal becomes a function
of dynamic dephasing from diffusion of water at the level of the
capillaries (13, 14). Using multi-slice, fast spin echo sequences the
signal contrast with BOLD imaging is a function of T2 and not
T2* at high field strengths. The extravascular signal surrounding
capillary beds and small vessels is more reflective of the metabolic
Frontiers in Neurology | Neurodegeneration June 2014 | Volume 5 | Article 94 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ferris et al. Imaging a mouse model of Huntington’s disease
FIGURE 1 | Mouse imaging system. Shown are the different components of
the mouse imaging system. Below are sagittal and axial views of an awake
mouse brain. Note the linearity along the Z -axis. The axial images taken from
a 22-slice RARE sequence (0.6 mm thickness) demonstrate complete brain
coverage from the olfactory bulbs to the brainstem. The mouse system was
provided by Animal Imaging Research, Holden, MA, USA.
changes in brain parenchyma than signal from large draining veins
helping to improve the localization of the signal changes (15).
The BOLD signal is linear and reproducible at stimulus intervals
of 1 s (16).
PROVOCATION PARADIGM – ODOR STIMULANT
Awake wild-type and transgenic mice were imaged for changes in
BOLD signal intensity in response to the odor of almond (ben-
zaldehyde), a stimulus to elicit the innate reward response (10).
All animals were “odor naïve” to this evolutionarily conserved
stimulus. We chose the almond odor because nuts are high in
calories and convey greater valance as compared to the other
odors. Moreover, the standard food chow is devoid of nuts, so
laboratory bred mice and the mice used in these studies have no
previous exposure to this food. In a recent study (10), brain acti-
vation maps from the odors of banana, rose, citrus, and almond
were dramatically different. Almond but not the other odors acti-
vated the hippocampus, amygdala, and limbic cortex. In a serial
dilution study for almond scent, we identified a threshold dilu-
tion of 100% benzaldehyde (1/10,000 v/v) that gives a significant
and consistent pattern of brain activity. This threshold dilution of
almond odor was used in this study. The time series for changes in
BOLD signal following presentation of almond odor were analyzed
using a repeated measures ANOVA followed by Fisher’s protected
least significant difference to limit experiment-wise error when
performing pairwise comparisons between genotypes.
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FIGURE 2 | Motion detection following acclimation. Time-course date
for motion detection from 29 awake mice imaged for 5 min is shown. Two
and a half minute into the scanning session, mice were challenged with 5%
carbon dioxide (see Figure 3). The data stability were estimated by a 3D
rigid body model with 6 degrees of freedom for translational and rotational
movement.
DATA ANALYSIS
Images were aligned and registered to a 3D mouse brain atlas,
which is segmented and labeled with 116 discrete anatomical
regions (Ekam Solutions, Boston, MA, USA). The alignment
process was facilitated by an interactive graphic user interface.
The registration process involved translation, rotation, and scaling
independently and in all three dimensions. Matrices that trans-
formed each subject’s anatomy were used to embed each slice
within the atlas. All pixel locations of anatomy that were trans-
formed were tagged with major and minor regions in the atlas.
This combination created a fully segmented representation of each
subject within the atlas. The inverse transformation matrix [Ti]−1
for each subject (i) was also calculated.
Using voxel-based analysis, the percent change in BOLD signal
for each independent voxel was averaged for all subjects. Each scan-
ning session consisted of 70 data acquisitions (whole brain scans)
with a period of 6 s each for a total lapse time of 420 s or 7 min.
The control window was the first 25 scan repetitions (2.5 min base-
line) while the odor stimulation window was 26–50 (min 2.5–5).
Statistical t -tests were performed on each voxel (ca. 15,000 in num-
ber) of each subject within their original coordinate system with a
baseline threshold of 2% BOLD change to account for normal fluc-
tuation of BOLD signal in the awake rodent brain (17). As a result
of the multiple t -test analyses performed, a false-positive detec-
tion controlling mechanism was introduced (18). This subsequent
filter guaranteed that, on average, the false-positive detection rate
was below our cutoff of 0.05. The t -test statistics used a 95% confi-
dence level, two-tailed distributions, and heteroscedastic variance
assumptions.
A composite image of the whole brain representing the average
of all subjects was constructed for each group for ROI analyses,
allowing us to look at each ROI separately to determine the BOLD
change and the number of activated voxels in each ROI. Statisti-
cal comparisons of different image acquisitions are compared to
baseline (see Table 1) using a non-parametric Kruskal–Wallis test
statistic followed by a Mann-Whitney U -test.
NORMALIZATION OF VOLUME OF ACTIVATION
The differences BOLD signal change in wild-type, HETzQ175, and
HOMzQ175 mice are reported in terms of volume of activation
or number of voxels per region of interest (ROI) or brain area.
In this study, the brain size across phenotypes can be significantly
different (see Table 2) from each other hence the volume of activa-
tion is normalized to volume of ROI. By normalizing to volume of
activation, we can compare across different phenotypes or within
group among different regions. Normalized volume of activation
was computed using following formula.
Normalized number of voxels in ROI
= Number of activated voxels in ROI× 100
Total number of voxels in ROI
.
CALCULATING THE VOLUMES OF DIFFERENT BRAIN AREAS
The volume of each brain area (ROI) was determined from the
high-resolution anatomical scan taken at the beginning of each
scanning session for each subject. The 3D segmented atlas pro-
vides the precise number of voxels (3D pixels) that combine
to fill the volume of each of the 116 ROIs or brain regions.
The dimensions of each voxel are calculated from the slice
thickness (0.75 mm), Voxel width (FOV in X direction/Number
of voxels in X direction) and Voxel height (FOV in Y direc-
tion/Number of voxels in Y direction) using the formula – Vol-
ume of voxel= voxel width× voxel height× slice thickness [ca.
0.097 mm× 0.097 mm× 0.750 mm= 0.00706 mm3]. Total num-
ber of voxels in each ROI were multiplied by volume of voxel to
compute total volume of brain region.
CARBON DIOXIDE CHALLENGE
To assess the strength of the BOLD signal in mice using HASTE and
to further characterize any differences between wild-type (n= 7),
HETzQ175 (n= 7), and HOMzQ175 (n= 10) mice in terms of
cerebrovascular reactivity animals were challenged with a 5% CO2
as a stimulus for a surrogate BOLD response. Carbon dioxide
causes a direct relaxation of cerebrovascular smooth muscle, caus-
ing a passive dilation with a subsequent increase in cerebral blood
flow. To this end, mice were imaged for a total of 5 min with pre-
sentation of 5% CO2 in ambient air at 2.5 min into the scanning
session. Data were analyzed using a repeated measures ANOVA
followed by Fisher’s protected least significant difference to limit
experiment-wise error when performing pairwise comparisons
between genotypes.
RESULTS
Shown in Table 1 are the positive BOLD signal changes represented
as a percentage of the total ROI volume (i.e., number of voxels
activated, divided by the total number of voxels in the 3D volume
of interest, times 100) for wild-type, HET, and HOMzQ175 mice
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Table 1 |Volume of activation in response to almond odor.
Region of interest (ROI) Wild-type Heter zQ175 Homo zQ175
Med Max Min Med Max Min Med Max Min pValue
Medial amygdaloid area 4 20 0 2 10 0 0 0 0 0.002
Ventral medial hypothalamic area 7 68 0 13 33 0 0 0 0 0.004
Frontal association ctx 10 23 3 0 14 0 0 11 0 0.006
Subiculum 3 27 0 1 4 0 0 2 0 0.008
Anterior hypothalamic area 3 27 0 4 14 0 0 0 0 0.008
Vestibular area 8 62 0 0 8 0 0 3 0 0.009
Endopiriform area 4 21 0 0 3 0 0 0 0 0.011
Extended amydala 1 11 0 0 3 0 0 0 0 0.012
Dentate gyrus 6 32 0 1 7 0 0 4 0 0.016
Anterior cingulate area 4 28 0 0 8 0 0 3 0 0.026
Lateral caudal hypothalamic area 4 39 0 4 25 0 0 11 0 0.026
Lateral posterior thalamic area 3 27 0 0 0 0 0 33 0 0.027
Primary somatosensory ctx 4 21 2 4 18 0 0.5 5 0 0.03
Secondary somatosensory ctx 1 14 0 3 6 1 0 4 0 0.032
Glomerular layer 6 29 1 3 40 1 0.5 10 0 0.044
Locus ceruleus 20 50 0 0 31 0 0 33 0 0.045
Principal sensory nucleus trigeminal 1 21 0 1 6 0 0 1 0 0.048
Medial mammillary area 23 82 0 3 31 0 0 35 0 0.059
Shown is a truncated list of 116 brain areas and their median (med), maximum (max), and minimum (min) number of voxels as a percentage of the total ROI volume
(i.e., number of voxels activated, divided by the total number of voxels in the 3D volume of interest, times 100) for wild-type, HET, and HOMzQ175 mice following
exposure to odor of almond. These volumes of activation for each brain region across genotypes were analyzed using a Newman–Keuls multiple comparisons test
statistic and rank order for their significance. p Values are presented on the far right column.The shaded gray columns highlight the median number of voxels for each
ROI and each genotype to aid in visual comparisons.
following exposure to odor of almond. The brain areas are rank
order for their significance and are truncated from a larger list of
116 regions of activation (for complete list see Table S1 in Sup-
plementary Material). The multiple comparison analysis showed
17 areas to be significantly different across conditions. Using the
mouse brain atlas, these 17 brain areas can be reconstructed into a
3D map as shown in Figure 3. This 3D presentation is the putative
neural circuit affected by the huntingtin gene mutation in response
to the odor of almond.
The odor of almond elicits an activation pattern across wild-
type, HET, and HOMzQ175 mice that suggests a gene-dose effect.
The statistical comparisons between conditions and their com-
posite pattern of activation are shown in Figure 4. The bar graphs
show the volume of activation as a percentage of the ROI volume
for each comparison. The areas of significance are shown in the
segmented, 3D color-coded and labeled image above. These 3D
areas are coalesced into a single yellow volume to the right show-
ing the location of the average, significant change in BOLD signal.
The post hoc analysis shows wild-type to have 14 brain areas that
differed in activation from HOMzQ175. These include the fore-
brain cortical areas (primary somatosensory, frontal association,
and anterior cingulate cortices), the hypothalamus (anterior, ven-
tral medial, and lateral caudal areas), the dentate, and subiculum
of the hippocampus and the glomerular layer of the olfactory
bulbs. When wild-type is compared to HETzQ175 only six areas
show a difference in BOLD activation. The frontal association and
anterior cingulate cortices, subiculum, and vestibular areas are
included showing that both HOM and HETzQ175 differ from
wild-type in the activation of these brain areas in response to the
odor of almond. HETzQ175 mice show nine brain area that differs
from HOMzQ175. Included are all hypothalamic areas, both pri-
mary and secondary somatosensory cortices and glomerular layer
of the olfactory bulb.
Since the provocation paradigm for these patterns of brain
activation was the odor of almond, the primary olfactory sys-
tem was reconstructed in 3D as shown in Figure 5. Shown below
are the 3D activation maps for each of the genotypes. As in
Figure 4 the red depicts the localization of the average signifi-
cant change in BOLD signal change for wild-type, HETzQ175,
and HOMzQ175 mice. These same data are presented as acti-
vation maps in 2D axial sections shown in Figure 6. The most
conspicuous difference between genotypes is the absence of BOLD
activation in the glomerular layer of the olfactory bulb confirmed
in Table 1.
Shown in Figure 7 are time-course data depicting the change
in BOLD signal intensity in the glomerular layer of the olfac-
tory bulb for wild-type, HETzQ175, and HOMzQ175 mice. Each
mouse in the wild-type (n= 9) and HETzQ175 (n= 9) showed a
significant change in BOLD signal intensity over time while two
of the eight HOMzQ175 mice showed no activation. A repeated
measures one-way ANOVA showed no significant main effect for
genotype (p= 0.067) but did show a differential effect of geno-
type on BOLD response following presentation of almond odor
[genotype× time: F (2,138)= 1.45 p= 0.0007].
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Table 2 | Brain volumes.
Region of interest (ROI) Wild-type Heter zQ175 Homo zQ175
X¯ Vol mm3 X¯ Vox # SE X¯ Vol mm3 X¯ Vox # SE X¯ Vol mm3 X¯ Vox # SE pValue
Caudate putamen 17.6 1171 102.9 19.6 1304 93.1 14.8 387 93.8 0.03
Caudal piriform ctx 5.9 392 35.7 6.5 435 31.5 4.9 325 33.5 0.03
Endopiriform area 1.0 67 7.6 1.2 78 6.5 0.8 54 6.4 0.03
Anterior cingulate area 2.8 186 18.5 3.2 213 16.3 2.4 158 16.6 0.03
Fimbria hippocampus 1.8 123 11.8 2.1 139 10.3 1.5 102 11.4 0.03
Globus pallidus 2.7 180 18.0 3.0 2CI1 15.1 2.2 147 15.4 0.03
Primary somatosensory ctx 20.7 1381 127.2 22.9 1528 109.8 17.4 1158 116.0 0.03
Superior colliculus 8.3 551 48.4 9.3 618 43.3 6.9 458 43.7 0.03
Median raphe area 1.3 86 7.2 1.5 97 6.8 1.1 73 6.2 0.03
Substantia nigra 1.6 109 10.1 1.8 119 7.8 1.4 90 9.0 0.03
Parietal ctx 0.5 31 2.6 0.6 37 3.4 0.3 23 3.1 0.03
Prelimbic ctx 1.7 112 10.9 1.9 126 9.3 1.4 96 9.8 0.03
CA1 hippocampus 8.0 536 47.6 8.9 590 42.2 6.8 454 43.4 0.03
Entorhinal ctx 16.0 1066 93.1 17.7 1180 82.2 13.5 303 93.8 0.04
Olfactory tubercles 1.8 120 11.5 2.0 136 11.5 1.5 99 10.4 0.04
Ventral medial hypothalamic area 0.7 43 4.6 0.9 57 4.4 0.6 39 4.3 0.04
Medial geniculate 1.3 87 8.3 1.5 97 6.6 1.1 72 6.7 0.04
Retrosplenial caudal ctx 4.3 285 25.4 4.7 312 23.4 3.5 233 24.2 0.04
Ventral pallidum 1.9 128 13.2 2.2 144 11.5 1.6 107 11.7 0.04
Auditory ctx 3.8 256 24.2 4.4 290 20.4 3.2 216 23.0 0.04
Medial amygdaloid area 2.0 132 12.7 2.2 149 11.2 1.7 111 10.7 0.04
Dentate gyrus 6.3 420 38.4 6.9 460 34.0 5.2 347 37.4 0.04
Lateral geniculate 0.7 46 4.2 0.8 52 4.1 0.5 36 3.7 0.04
Basal amygdaloid area 3.1 206 20.2 3.5 230 18.2 2.6 173 17.8 0.04
Secondary somatosensory ctx 5.6 370 34.1 6.1 407 30.9 4.6 308 31.5 0.04
Lateral rostral hypothalamic area 2.9 191 17.3 3.2 214 15.3 2.4 160 17.1 0.04
Periaqueductal gray 5.3 352 32.2 5.8 388 28.9 4.4 296 28.5 0.04
Central amygdaloid area 1.8 122 11.4 2.0 133 9.7 1.5 103 10.3 0.04
Anterior hypothalamic area 2.3 152 13.1 2.5 169 11.3 2.0 131 12.1 0.04
Insular rostral ctx 5.9 392 34.4 6.5 431 31.6 4.9 326 32.7 0.04
Mesencephalic reticular formation 6.9 458 42.0 7.5 503 34.3 5.7 383 37.3 0.04
Ventral tegmental area 0.6 39 4.4 0.6 42 2.9 0.5 31 3.5 0.04
Subiculum 7.2 478 44.3 7.9 525 37.4 6.0 399 33.1 0.04
Ventral thalamic area 4.9 328 28.6 5.5 364 26.9 4.2 278 27.5 0.04
Inferior colliculus 6.5 436 40.8 7.2 482 34.2 5.6 370 36.6 0.05
Orbital ctx 5.5 367 33.2 6.1 407 29.6 4.7 311 30.4 0.05
CAS hippocampus 3.4 225 21.9 3.8 251 19.1 2.8 185 20.1 0.05
Rostral piriform ctx 8.1 540 47.9 8.9 590 42.8 6.7 443 47.0 0.05
Visual 1 ctx 13.6 303 82.6 14.7 378 69.4 11.6 773 75.9 0.05
Dorsal raphe 0.6 37 3.5 0.6 40 3.0 0.5 31 3.0 0.05
Primary motor ctx 5.1 337 32.6 5.7 377 30.6 4.3 287 31.7 0.05
Paraventricular hypothalamic area 0.2 10 1.4 0.2 12 1.1 0.1 8 1.2 0.05
Pituitary 0.9 57 6.4 1.0 68 5.4 0.7 48 5.4 0.06
Shown is a truncated list of 116 brain areas and their mean volume (cubic millimeter), mean voxel number (#) with standard error (SE) for wild-type, HET, and
HOMzQ175 mice. These brain volumes for each ROI for each genotype were analyzed using a Newman–Keuls multiple comparisons test statistic and rank order for
their significance. p Values are presented on the far right column.The shaded gray columns highlight the mean volume for each ROI and each genotype to aid in visual
comparisons.
Shown in Figure 8 are changes in BOLD signal over time in
response to 5% CO2 challenge for wild-type (n= 7), HETzQ175
(n= 7), and HOMzQ175 (n= 10) mice. For both wild-type and
HETzQ175 conditions, one out of the seven animals did not
response to CO2 challenge, i.e., no activated voxels in the pri-
mary somatosensory cortex, while 4 out of the 10 animals in
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FIGURE 3 | Huntington neural circuit of dysregulation in response to
almond odor. The 17, color-coded and labeled 3D volumes shown above were
identified from 116 brain areas in the mouse atlas as having a significantly
different BOLD signal between genotypes in response to the odor of almond.
These areas are listed inTable 1. The central image is a coronal view of a
translucent shell of the brain showing the total composite and location of the
different 3D volumes of interest. Surrounding this are different layers of the
neural circuit showing a caudal (deepest) to dorsal perspective of the different
brain volumes. The panels on the top show the neural circuit in different
orthogonal directions.
the HOMzQ175 genotype did not respond to CO2 challenge. A
repeated measures one-way ANOVA demonstrated that the time-
course of BOLD responses to CO2 differed by genotype [geno-
type× time: F (2,98)= 1.65, p= 0.001]. Post hoc pairwise compar-
isons at each repetition indicated that the differential effect of
genotype on BOLD response occurred in the first five repetitions
(30 s) following onset of the CO2 challenge. HOMzQ175 rats dis-
played diminished BOLD responses compared to both wild-type
and HETzQ175 rats during repetitions 26–30 (p< 0.05 for all
comparisons).
Shown in Table 2 are the comparisons in brain volumes across
wild-type, HET, and HOMzQ175 mice. The brain areas are rank
order for their significance and are truncated from a larger list of
116 regions of activation (for complete list see Table S2 in Sup-
plementary Material). The multiple comparison analysis showed
46 brain areas to differ significantly in volume across pheno-
types. Post hoc analysis using Fisher’s PLSD showed that the
significant differences (p< 0.05) were all between the HET and
HOMzQ175 mice and not between wild-type vs. HET or wild-type
vs. HOMzQ175 mice.
DISCUSSION
We chose to challenge wild-type, HET, and HOMzQ175 mice with
the smell of almond as a means of differentiating their brain activ-
ity toward a stimulus with a high emotional and motivational
valence. In human and animal fMRI studies, desirable foods have
been identified as motivating/rewarding stimuli activating limbic
areas, particularly the orbital frontal, cingulate and insular cor-
tices, amygdala, and striatum (10, 19–22). In a recent study, we
were able to show that rats possess an innate sensitivity to energy
rich food (such as almonds) and that this results in neural activa-
tion of the olfactory system and its connections to other brain areas
(10). In a pilot study using serial dilutions of 100% benzaldehyde
(almond odor), we identified a threshold dilution (1/10,000 v/v)
that gave a robust and consistent pattern of brain activity to wild-
type and HET Q175 mice, while the responsiveness of HOM Q175
was less (Figures 6 and 7) particularly in the glomerular layer of
the olfactory bulb (Figure 4; Table 1).
Loss in olfactory discrimination and detection sensitivity are
common with HD (23–26) and may appear prior to significant
motor or cognitive dysfunction (27). Individuals at risk for HD,
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FIGURE 4 | Gene-dose effect in response to almond odor.
(Continued)
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FIGURE 4 | Continued
The figure is parsed into three panels based on the significant differences
between wild-type and HOMzQ175 (top panel), wild-type and HETzQ175
(middle panel), and HETzQ175 and HOMzQ175 (lower panel). Areas that
are significantly different for each comparison are presented as 3D
color-coded and labeled maps above with the individual bars graphs for
each brain area below. These 3D color-coded volumes are coalesced into
a single yellow volume to the right of each panel showing the location of
the average, significant change in BOLD signal (red). These 3D activation
maps are data taken from wild-type (n=9) for the top and middle panels.
The 3D activation map in the bottom panel is data taken from HETzQ175
(n=9). The bar graphs show the volume of activation as a percentage of
the brain area volume for each statistical comparison using
Mann-Whitney U -test.
FIGURE 5 | 3D activation maps of the primary olfactory system.
Shown is a 3D color representation of the different brain areas
comprising the primary olfactory system. The layout is similar to
that described in Figure 4. In the three illustrations below, these
brain areas are coalesced into a single yellow volume. The red
shows the location of the average, significant increase in BOLD
signal in response to the presentation of almond odor for each
genotype.
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FIGURE 6 | 2D activation maps of the primary olfactory system. Shown
are rostral (top) to caudal (bottom) axial sections taken from the mouse brain
atlas and the location of the average, significant increase in BOLD signal for
each genotype in response to the odor of almond. These are the same data
shown in figure but with a 2D perspective to shown the signal location with
the 3D volume.
show a dysfunction in source memory for olfaction, i.e., the con-
text associated with the memory (28). Transgenic mouse models
of HD shows micro-aggregates of huntingtin proteins in primary
olfactory system (29) and a reduction in structural neuroplasticity
in olfactory cortex that may be causally related to the impair-
ment in olfactory memory (24). These abnormalities may have
contributed to the functional differences observed in the present
study although imaging these phenotypes at 1 year of age preclude
us from drawing any conclusions about olfaction as a biomarker
of pre-symptomatic HD.
The imaging data suggest a “gene-dose effect,” i.e., HETzQ175
mice show a reduction in brain activity from wild-type that is
further reduced in HOMzQ175 mice. Indeed, of the 17 brain
areas identified as responding differently to almond odor across
genotypes, HOMzQ175 showed the greatest differences between
wild-type and HETzQ175. Since the HETzQ175 form of HD is
most prevalent in the population and is characterized by slow dis-
ease progression transitioning from a pre-symptomatic to symp-
tomatic phenotype, greater emphasis is placed on understanding
the HETzQ175 genotype. Only 6 out of 17 areas identified in
Figure 3 were different between wild-type and HETzQ175 mice.
These included the frontal association cortex, anterior cingulate
cortex, subiculum of the hippocampus, lateral posterior thalamus
and vestibular area, and locus coeruleus of the medulla oblon-
gata. None of these areas were different between HETzQ175 and
HOMzQ175 mice, so they represent brain areas deviating from
the norm during disease progression and antecedent to any HD
phenotype in the HETzQ175 mouse model (6, 7). Interestingly,
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FIGURE 7 | Blood oxygen level dependent signal change over time in
response to almond odor. Shown are the changes in the BOLD signal in
the glomerulus of the olfactory bulb for each genotype in response to the
presentation of almond odor following a 2 min baseline of 20 image
acquisitions. While the time series are similar in that each genotype shows
a comparable baseline and onset of activation there is a significant
difference between the time series and an interaction between the time
series and genotypes as shown in the two-way repeated measures
ANOVA. Each time point is the mean BOLD signal±SEM.
FIGURE 8 | Blood oxygen level dependent signal change to carbon
dioxide challenge. Shown are time-course data for each genotype for the
percentage change in BOLD signal intensity in the somatosensory cortex in
response to the challenge of 5% carbon dioxide. Each image acquisition is
the mean±SEM.
the frontal association and cingulate cortices were shown to have
reduced metabolic activity based on 2DG autoradiography in the
R6/2 mouse model of HD (30).
In HD, striatal and cortical atrophy are the most common find-
ings, and they correlate with cognitive deficits in attention, work-
ing memory, and executive functions (2). Cognitive decline is a
well documented sign of early HD (31) even affecting individual at
risk for HD (32–34). A time-dependent and gene-dose dependent
change in cognitive function is a common feature of transgenic
mouse models of HD (6, 7, 35–38). In wild-type mice, activation
of subcortical and cortical brain areas identified with quantita-
tive autoradiography for 2DG involve time-dependent changes in
brain activity associated with memory consolidation. These brain
areas include frontal association cortex, anterior cingulate, sensory
motor cortices together with thalamus and hippocampus (39). All
of these areas are represented in the brain map shown in Figure 3
reflecting areas differing in odor-induced activation across geno-
types. Transgenic mouse models of HD suggest dysfunction in
hippocampal dependent short term memory (40) and increased
activity in local field potentials in the subiculum, dentate gyrus,
and temporal cortex with an enhanced susceptibility to autogenic
seizures (30). Neurotransmission between cortical and subcortical
areas is affected in HD. Alterations in dendritic spine survival and
density in cortical neurons characteristic of mouse model of HD
accompany early symptoms of HD (41). There is also evidence
that altered excitatory and inhibitory inputs to pyramidal neurons
in the cortex are characteristics of disease progression in vari-
ous mouse models of HD, which points to early signs of synaptic
dysregulation involving glutamate and GABA signaling (42, 43).
Changes in brain morphology and reduced brain volume, par-
ticularly in the area of the striatum and cortex are common features
of disease progression in HD (44–46). Studies in mouse models of
HD mice also report significant volume loss in the striatum, and
neocortex as compared to wild-type (30, 47–49). In our studies,
the use of the 3D segmented atlas to calculate the average vol-
ume for 116 different brain areas across wild-type, HETzQ175,
and HOMzQ175 mice corroborated what has been reported by
Heikkinen and coworkers for striatal volumes across genotypes in
zQ175 mice (7). At 10 months of age HOMzQ175 mice show a
striatal volume (caudate/putamen) of just under 16 mm3 as com-
pared to a wild-type of volume of just under 19 mm3, a decrease of
ca. 15%. In these studies, we report striatal volume of ca. 15 mm3
for HOMzQ175 and ca. 18 mm3 for wild-type or about a 17%
reduction in volume. The major difference between studies is that
we did not observe a reduction in ROI volumes in HETzQ175
mice. Indeed, there were no significant differences in ROI volumes
between wild-type and HETzQ175 mice.
One of the more interesting aspects of this study is the pre-
sentation of almond odor, to “odor naïve” animals differing only
in the protein expression of the single huntingtin gene. From 116
different brain areas, only 17 were found to differ in their activity
when comparing wild-type, HETzQ175, and HOMzQ175 geno-
types as shown in Figure 3. When viewed in the context of an
integrated neural circuit, the areas of activation do not comprise
a distinguishing “finger print” of brain function, e.g., motivation
and reinforcement, pain, fear, or any particular neurochemical
signaling pathway like dopamine or serotonin. Indeed, the cau-
date/putamen, thalamus, CA3 and CA1 of the hippocampus and
much of the cortex are targeted areas in HD showing dramatic
changes in function and morphology with disease progression.
Yet, these areas were not identified with this almond odor provo-
cation paradigm. What then is the connection, if any, between the
glomerulus of the olfactory bulb, frontal association cortex, and
anterior cingulate in the rostral part of the brain to the vestibular
area, spinal trigeminal nucleus, and locus coeruleus in the most
caudal part of the brain and the hypothalamus and amygdala in
between? The answer may be found in a study by Fujinaga and
coworkers mapping the neuroanatomical distribution of HAP1
mRNA in the male mouse brain (50). HAP1 can complex with
Htt protein in the cytoplasm of neurons. Together, they regu-
late autophagosome transport, bidirectional movement of vesicles
along the neuron axis involved in degradation of cellular debris
(51). The presence of mutant HTT protein or reduction in HAP1
can impair the Htt/HAP1 interaction and disrupt autophagosome
transport potentially leading to neuronal death (51). However,
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there are multiple lines of evidence that HAP1 is not contributing
to the neuropathology of mutant Htt (52–54); instead, mutant Htt
may be impacting the normal function of HAP1 (55, 56). To this
point, HAP1 is not found in CA3/CA1 of hippocampus, thalamus,
or much of the cortical mantel with only small amounts in the
somatosensory cortex and caudate/putamen. Instead, its highest
concentrations are found in a majority of those areas identified in
Figure 3. Hence, the brain activity across wild-type, HETzQ175,
and HOMzQ175, differentiated by the odor of almond, maps onto
the neuroanatomical localization of HAP1. Might there be some
functional relevance to this observation?
While HAP1 has been shown to function in intracellular traf-
ficking of pro-brain-derived-neurotrophic factor (57, 58), epider-
mal growth factor (59), and gamma-aminobutyric acid type A
receptor (60), to note a few, it also directly impacts animal behavior
via the hypothalamus. It was proposed by Chan and coworkers that
this putative neural circuit connected by HAP1 expressing neu-
rons functions in the control of instinctual behaviors, e.g., feeding,
sex, and aggression, that involve autonomic and neuroendocrine
processes (53). This notion was supported by the finding that
transgenic mice deficient in HAP1, suffer from postnatal malnu-
trition and morbidity because of a dysfunction in feeding behavior.
The link between HAP1 and feeding behavior was subsequently
corroborated by others (56, 61). Given the odor stimulant used in
the present study (almond) is intrinsically rewarding, there may be
a causal link between the pattern of BOLD activation that differ-
entiates the wild-type and HD genotypes, to the neuroanatomical
localization of HAP1.
CAVEATS AND DATA INTERPRETATION
For any imaging study on awake animals, the issues and conse-
quences related to the stress of head restraint and restricted body
movement must be considered. Protocols have been developed to
help lessen the stress of an imaging study by acclimating animals
to the environment of the MR scanner and the restraining devices
helping to reduce stress hormones levels and measures of sympa-
thetic autonomic activity (12, 62). These acclimation procedures
put animals through several simulated imaging sessions and have
been used to study sexual arousal in monkeys (63), generalized
seizures in rats and monkeys (64, 65), and exposure to psychos-
timulants like cocaine (66–68), nicotine (69), and apomorphine
(62, 70). Nonetheless, one must consider the experimental con-
found that exists with low levels of arousal and stress associated
with imaging awake animals. Indeed, the different phenotypes in
this study may have very different sensitivities to restraint stress.
Another consideration when interpreting the data is the mor-
phological changes in brain structure that occur over time in
wild-type, HET, and HOMzQ175 mice as noted above. This
raises the possibility that regional differences in brain volume in
HOMzQ175 may have influenced the BOLD signal analysis par-
ticularly when the data is reported as volume of activation, i.e.,
number of voxels activated in a 3D brain volume. To control for
this possibility,we normalized the volume of activation to the brain
volume of interest for each subject prior to statistical comparisons
for all three genotypes.
The data in Figure 8 clearly show that the HOMzQ175 have
diminished vascular responsivity to CO2 challenge. This raises the
possibility that the blunted BOLD response in HOMzQ175 mice
may be due to ineffective coupling of blood/flow and metabo-
lism. Cepeda-Prado and coworkers (30) using measures of cerebral
blood volume (CBV) correlated with neuronal excitability, sug-
gest there is normal neurovascular coupling in HD mice, but a
paradoxical decrease in metabolism with very high CBV sugges-
tive of impaired neurometabolic coupling. The implications are
far reaching and may underscore a mechanism that contributes
to loss of cognitive function with disease severity. There are no
reports in the human or animal imaging literature that we know
of that show challenges with CO2.
SUMMARY
The prospective capability of animal imaging to follow changes
in brain neurobiology following genetic or environmental insult
has great value in the field of HD research as one can follow the
etiology and pathophysiology of disease progression. In addition,
the combination of awake fMRI in mice with an imaging genetics
approach (71) represents a powerful experimental strategy that
permits the identification of the affect of single gene mutations on
neural circuits regulating emotion and cognition. While imaging
genetics in humans takes advantage of natural polymorphisms to
examine the genetic basis of differences in neural activation, imag-
ing genetics in transgenic animals is a more targeted approach that
offers the potential to investigate the contribution of a single gene
to neural response patterns. When this neural activity is combined
with a 3D segmented, annotated MRI mouse atlas it is possible to
reconstruct distributed integrated neural circuits both in 3D and
2D that “finger print” the pattern of brain activity to a provocation
paradigm as is the case here.
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